Drug Trial Radar · NCT07443202
Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)
Last checked: Nov 20, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
155
Planned (sponsor's estimate)
Start
Dec 5, 2025
Primary completion
Dec 31, 2026
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Tarsus Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate lotilaner treatment in patients with ocular rosacea.
Conditions
- Ocular Rosacea
Interventions
lotilanerDrug
lotilaner
VehicleDrug
Vehicle of lotilaner
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment Emergent Adverse EventsTime frame: Week 16
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Site
Houston, Texas
Site
Lynchburg, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.